Table of Content


Chapter 1 Introduction
1.1 Overview
1.2 Study Goals and Objectives
1.3 Reasons for Doing This Study
1.4 What’s New in This Update?
1.5 Scope of Report
1.6 Information Sources
1.7 Methodology
1.8 Geographic Breakdown
1.9 Analyst’s Credentials

Chapter 2 Summary and Highlights
Chapter 3 Market Dynamics
3.1 Market Drivers
3.1.1 Technological Advancements in the Analysis of Glycans
3.1.2 Rising Prevalence of Chronic Disorders Globally
3.1.3 Increasing R&D Investment by Pharma Companies
3.2 Market Restraints
3.2.1 Challenges in Glycobiology
3.3 Market Opportunities
3.3.1 Inorganic Strategies among Market Players
Chapter 4 Market Overview
4.1 Overview
4.1.1 Glycobiology
4.1.2 Significance of Glycan
4.1.3 Function of Glycans and Their Biological Significance
4.1.4 Structural Role of Glycans
4.1.5 Research Tools for Glycobiology Studies
4.1.6 Structural Analysis of Glycans
4.1.7 Glycomics as Part of Glycobiology Research
4.1.8 Chemical and Enzymatic Synthesis of Glycans and Glycoconjugates
4.1.9 Bioinformatics and Database Resources for Glycobiology Research
4.2 Current Market Trends
4.2.1 Protein and Glycan Glycoengineering
4.2.2 Engineering Glycans and Glycan Mimics as Therapeutic Agents
4.2.3 Glycobiology and Drug Delivery
4.2.4 Oligosaccharide Libraries for Drug Discovery Research
4.2.5 Glyconutrients as Therapeutics
4.3 Recent Strategic Alliances
4.4 Emerging Technologies
4.4.1 Glycans in Medicine and Biotechnology
4.4.2 Glycans in Nanotechnology, Bioenergy, and Materials Science
Chapter 5 Impact of COVID-19 on Market
5.1 Overview
5.2 COVID-19 Crisis
5.2.1 Impact on Market for Glycobiology
5.2.2 COVID-19 Measures
Chapter 6 Glycobiology Therapeutics Market
6.1 Overview
6.1.1 Subcategories of Glycobiology Therapeutics
6.1.2 Therapeutic Glycoproteins
6.1.3 Glycan Therapeutic Approaches to Metabolic Diseases
6.1.4 Therapeutic Applications of Glycosaminoglycans
6.1.5 Carbohydrate-based Vaccines and Glycans as Vaccine Components
6.1.6 Blocking Glycan Recognition in Diseases
6.1.7 Transfusion and Transplantation Rejection by Anti-glycan Antibodies
Chapter 7 Glycobiology Diagnostics Market
7.1 Overview
7.1.1 Glycobiomarkers and Autoimmunity
7.1.2 Glycobiomarkers in Inflammatory Bowel Disease
7.1.3 Autoantibodies Against Neuronal Glycans in Certain Neuropathies
7.1.4 Glycobiology Markers in Cardiovascular Diseases
7.1.5 Role of Glycans in the Histopathology of Alzheimer’s Disease
7.1.6 Glycobiomarkers and Asthma
7.1.7 Glycobiomarkers in Infectious Disease Testing
7.1.8 Market Potential for Glycobiology-based Biomarkers and Diagnostic Tests
7.1.9 Glycobiology-based Cancer Biomarkers and Diagnostic Development
7.1.10 Carbohydrates as Potential Serum Biomarkers
7.1.11 Current Glycobiology-based Diagnostics on the Market
7.1.12 Companies with Glycobiology Diagnostic Platforms and Products in Development
7.1.13 Market for Glycobiology-based Diagnostics
Chapter 8 Glycobiology Reagents and Tools Market
8.1 Overview
8.1.1 Analytical and Chromatography Techniques
8.1.2 Glycan Arrays
8.1.3 Lectin Arrays
8.1.4 Glycobiology Kits
8.1.5 Reagents for Glycobiology Research
8.1.6 Carbohydrates: Monosaccharides, Oligosaccharides and Other Reagents
Chapter 9 Market Breakdown by Region
9.1 Overview
9.1.1 North America
9.1.2 Europe
9.1.3 Asia-Pacific
9.1.4 Rest of the World
Chapter 10 Analysis of Market Opportunities
10.1 Porter’s Five Forces Analysis
10.1.1 Threat of New Entrants
10.1.2 Threat of Substitutes
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining Power of Buyers
10.1.5 Degree of Competition
Chapter 11 Competitive Landscape
Chapter 12 Company Profiles
12.1 Major Companies
AGILENT TECHNOLOGIES
AMSBIO LLC
BIO-TECHNE
ISOSEP
LUDGER LTD.
MERCK KGAA
NEW ENGLAND BIOLABS
TAKARA BIO INC.
THERMO FISHER SCIENTIFIC INC.
WATERS CORP.
Chapter 13 Appendix: Acronyms



List of Figures

List of Figures
Summary Figure : Global Market Shares of Glycobiology, by Segment, 2021
Figure 1 : Emerging Glycomics Technologies
Figure 2 : Cases of Diabetes Worldwide, by Type, 2019
Figure 3 : Global Prevalence of Diabetes, by Type, 2018-2040
Figure 4 : Numbers and Shares of New Cancer Cases, Women, 2020
Figure 5 : Numbers and Shares of New Cancer Cases, Men, 2020
Figure 6 : Schematic Presentation of O- and N-linked Glycans on Protein Receptor
Figure 7 : Global Market for Glycobiology Therapeutics, 2019-2027
Figure 8 : Global Market for Glycobiology Diagnostics, 2019-2027
Figure 9 : Global Market for Glycobiology Reagents and Tools, 2019-2027
Figure 10 : Global Market Shares of Glycobiology, by Region, 2021
Figure 11 : North American Market Shares of Glycobiology, by Country, 2021
Figure 12 : Cancer Diagnosis Share in Europe, by Gender, 2020
Figure 13 : European Market Shares of Glycobiology, by Country, 2021
Figure 14 : Asia-Pacific Market Shares of Glycobiology, by Country, 2021
Figure 15 : Global Market Shares of Glycobiology, by Company, 2021
Figure 16 : Agilent Technologies: Annual Revenue, 2019-2021
Figure 17 : Agilent Technologies: Revenue Share, by Segment, 2021
Figure 18 : Agilent Technologies: Revenue Share, by Region, 2021
Figure 19 : Bio-Techne: Annual Revenue, 2019-2021
Figure 20 : Bio-Techne: Revenue Share, by Business Segment, 2021
Figure 21 : Bio-Techne: Revenue Share, by Region, 2021
Figure 22 : Merck KGaA: Annual Revenue, 2019-2021
Figure 23 : Merck KGaA: Revenue Share, by Business Segment, 2021
Figure 24 : Merck KGaA: Revenue Share, by Region, 2021
Figure 25 : Takara Bio Inc.: Annual Revenue, 2019-2021
Figure 26 : Takara Bio Inc.: Revenue Share, by Segment, 2021
Figure 27 : Takara Bio Inc.: Revenue Share, by Region, 2021
Figure 28 : Thermo Fisher Scientific Inc.: Annual Revenue, 2019-2021
Figure 29 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2021
Figure 30 : Thermo Fisher Scientific Inc.: Revenue Share, by Region, 2021
Figure 31 : Waters Corp.: Annual Revenue, 2019-2021
Figure 32 : Waters Corp.: Revenue Share, by Segment, 2021
Figure 33 : Waters Corp.: Revenue Share, by Region, 2021

List of Tables

List of Tables
Summary Table : Global Market for Glycobiology, by Segment, Through 2027
Table 1 : Global Diabetes Prevalence, Estimates and Projections, 2019-2045
Table 2 : Cases of Diabetes Worldwide, by Type, 2019
Table 3 : Global Prevalence of Diabetes, by Type, Through 2040
Table 4 : Global HIV Epidemic, by Age Group, 2020
Table 5 : Market Players: R&D Investment, 2019-2021
Table 6 : Classification of Carbohydrates
Table 7 : Examples of Glycosylation Deficiency and Their Pathological Effect
Table 8 : Experimental Approaches to Studying Glycans
Table 9 : Examples of Inhibitors/Modulators Used in Glycobiology Research
Table 10 : Separation and Identification Techniques Used for Glycan Analysis
Table 11 : Bioinformatics and Database Resources for Glycobiology Research
Table 12 : Strategic Alliances in the Market for Glycobiology, 2020-2022
Table 13 : Approved Glycobiology-related Treatments and Carbohydrate-based Drugs
Table 14 : Global Market for Glycobiology Therapeutics, by Region, Through 2027
Table 15 : Glycobiology-based Markers
Table 16 : Global Death Share, by Various Cancer Types, 2015
Table 17 : FDA-approved Cancer Biomarkers Currently Used in Clinical Practice
Table 18 : Examples of Potential Glycoprotein Cancer Biomarkers
Table 19 : Companies with Diagnostic Products in Development Based on Glycobiology Research
Table 20 : Global Market for Glycobiology Diagnostics, by Region, Through 2027
Table 21 : Companies Offering Glycobiology Reagents
Table 22 : Global Market for Glycobiology Reagents and Tools, by Region, Through 2027
Table 23 : Global Market for Glycobiology, by Region, Through 2027
Table 24 : Diabetes Estimates in North America, by Country, 2000-2045
Table 25 : Influenza Disease Burden, by Age Group, U.S., 2019 and 2020 Influenza Season
Table 26 : North American Market for Glycobiology, by Country, Through 2027
Table 27 : Diabetes Estimates in Europe, by Country, 2000-2045
Table 28 : European Market for Glycobiology, by Country, Through 2027
Table 29 : Tuberculosis Burden of Asian Countries, by Country, 2019
Table 30 : Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
Table 31 : Asia-Pacific Market for Glycobiology, by Country, Through 2027
Table 32 : Diabetes Estimates in RoW, by Country, 2000-2045
Table 33 : New Cancer Cases in Africa, by Cancer Type, 2020 and 2024
Table 34 : Porter’s Five Forces Analysis: Glycobiology Market
Table 35 : Agilent Technologies: Product Portfolio
Table 36 : Agilent Technologies: Key Developments, 2016-2020
Table 37 : AMSBIO LLC: Product Portfolio
Table 38 : AMSBIO LLC: Key Developments, 2022
Table 39 : Bio-Techne: Product Portfolio
Table 40 : IsoSep: Product Portfolio
Table 41 : Ludger Ltd.: Product Portfolio
Table 42 : Ludger Ltd.: Key Developments, 2022
Table 43 : Merck KGaA: Product Portfolio
Table 44 : Merck KgaA: Key Developments, 2020 and 2021
Table 45 : New England Biolabs: Insulin Product Portfolio
Table 46 : Takara Bio Inc.: Product Portfolio
Table 47 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 48 : Thermo Fisher Scientific Inc.: Key Developments, 2020
Table 49 : Waters Corp.: Product Portfolio
Table 50 : Acronyms Used in This Report